[go: up one dir, main page]

WO2014169845A3 - 4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用 - Google Patents

4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用 Download PDF

Info

Publication number
WO2014169845A3
WO2014169845A3 PCT/CN2014/075683 CN2014075683W WO2014169845A3 WO 2014169845 A3 WO2014169845 A3 WO 2014169845A3 CN 2014075683 W CN2014075683 W CN 2014075683W WO 2014169845 A3 WO2014169845 A3 WO 2014169845A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrid
pyrazolo
dihydro
ones
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/075683
Other languages
English (en)
French (fr)
Other versions
WO2014169845A2 (zh
Inventor
魏用刚
邱关鹏
卢泳华
余彦
雷柏林
王松
黄清平
高秋
楚洪柱
祝国智
罗新峰
倪丽军
陈娅姝
邓炳初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN201480003262.1A priority Critical patent/CN105026392B/zh
Publication of WO2014169845A2 publication Critical patent/WO2014169845A2/zh
Publication of WO2014169845A3 publication Critical patent/WO2014169845A3/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种通式（I）所示4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用，通式（I）化合物中的各取代基的定义与说明书中的定义相同。
PCT/CN2014/075683 2013-04-19 2014-04-18 4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用 Ceased WO2014169845A2 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480003262.1A CN105026392B (zh) 2013-04-19 2014-04-18 4,5‑二氢‑吡唑并[3,4‑c]吡啶‑2‑酮衍生物、其制备方法以及应用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201310138026 2013-04-19
CN201310138026.8 2013-04-19
CN201310372920 2013-08-23
CN201310372920.1 2013-08-23
CN201310428690.6 2013-09-18
CN201310428690.6A CN104109165A (zh) 2013-04-19 2013-09-18 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用

Publications (2)

Publication Number Publication Date
WO2014169845A2 WO2014169845A2 (zh) 2014-10-23
WO2014169845A3 true WO2014169845A3 (zh) 2014-12-11

Family

ID=51706170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/075683 Ceased WO2014169845A2 (zh) 2013-04-19 2014-04-18 4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用

Country Status (2)

Country Link
CN (2) CN104109165A (zh)
WO (1) WO2014169845A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064497A1 (en) * 2015-07-20 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Dimer impurities of apixaban and method to remove them
HRP20201405T1 (hr) 2016-03-17 2020-11-27 F. Hoffmann - La Roche Ag Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
CN107474030B (zh) * 2016-06-08 2021-03-30 首都医科大学 华法林-阿司匹林缀合物，其合成，抗血栓活性和应用
CN109232596B (zh) * 2018-09-05 2020-03-17 大连九信精细化工有限公司 一种二苯并呋喃咔唑的合成方法
CN110143914B (zh) * 2019-06-21 2022-03-29 常州恒邦药业有限公司 一种阿哌沙班中间体的制备方法
KR20240014059A (ko) 2021-05-27 2024-01-31 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 퀴놀린아민 화합물, 이의 제조 방법 및 약제에서의 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391575A (zh) * 1998-12-23 2003-01-15 杜邦药品公司 作为凝血因子xa抑制剂的含氮杂双环
US20100048611A1 (en) * 2006-05-31 2010-02-25 Bayer Healthcare Ag Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000655A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors
SI1427415T1 (sl) * 2001-09-21 2009-12-31 Bristol Myers Squibb Co Sestavine, ki vsebujejo laktame in njihovi derivati kot inhibitorji faktorja xa
TW200303201A (en) * 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
CN101065379B (zh) * 2004-09-28 2011-05-11 布里斯托尔-迈尔斯斯奎布公司 制备4,5-二氢-吡唑并[3,4-c]吡啶-2-酮的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1391575A (zh) * 1998-12-23 2003-01-15 杜邦药品公司 作为凝血因子xa抑制剂的含氮杂双环
US20100048611A1 (en) * 2006-05-31 2010-02-25 Bayer Healthcare Ag Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof

Also Published As

Publication number Publication date
CN105026392B (zh) 2017-05-10
WO2014169845A2 (zh) 2014-10-23
CN104109165A (zh) 2014-10-22
CN105026392A (zh) 2015-11-04

Similar Documents

Publication Publication Date Title
MY191628A (en) Novel triazolo[4,5-d]pyrimidine derivatives
DK3077397T3 (da) 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
WO2014083438A3 (en) Nitric oxide increasing nutritional supplements and methods
EP3064416A4 (en) Vehicle, and method of manufacturing same
EP2968311A4 (en) OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
WO2014194034A3 (en) Novel metalloproteases
EP2829368A3 (en) Robot and manufacturing method of the same
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
EP2829369A3 (en) Robot and manufacturing method of the same
CA2905610C (en) Hyaluronic acid derivatives
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
WO2012116010A3 (en) Antibiotic tolerance inhibitors
HK1208677A1 (zh) 具有咪唑-聯苯-咪唑核心之抗病毒化合物
WO2014169845A3 (zh) 4，5−二氢−吡唑并【3，4−c】吡啶−2−酮衍生物、其制备方法以及应用
EP3038660A4 (en) Compound of glycosaminoglycan and its preparation method as well as application
PH12015502118A1 (en) Pyridin-4-yl derivatives
NZ716154A (en) Tricyclic benzoxaborole compound, preparation method therefor, and use thereof
WO2016009401A3 (en) Preparation of tedizolid phosphate
EP3053475A4 (en) Manufacturing device and manufacturing method for fastener stringer, as well as fastener stringer
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂
EP3003078A4 (en) Garment part, garment incorporating such garment part and method of manufacturing same
EP3005443B8 (en) Battery assembly and method of manufacturing the same
WO2015095240A3 (en) Biosynthesis of 1-undecence and related terminal olefins
HK1212978A1 (zh) 芥子酸的新型衍生物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480003262.1

Country of ref document: CN

122 Ep: pct application non-entry in european phase

Ref document number: 14786038

Country of ref document: EP

Kind code of ref document: A2